UroGen Pharma End Period Cash Flow Over Time
| URGN Stock | USD 12.66 0.18 1.44% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out UroGen Pharma Performance and UroGen Pharma Correlation. UroGen |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities End Period Cash Flow Analysis
Compare UroGen Pharma and related stocks such as Eliem Therapeutics, Inhibrx, and Merrimack Pharmaceuticals End Period Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INBX | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 13.5 M | 2.1 M | 11.5 M | 128.7 M | 131.3 M | 273.9 M | 277.9 M | 291.8 M |
| CELC | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.9 M | 2.6 M | 15.9 M | 18.7 M | 11.6 M | 84.3 M | 24.6 M | 30.7 M | 24.4 M |
| ELVN | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 7.4 M | 4.9 M | 130.4 M | 110.1 M | 75.6 M | 100.2 M | 68.9 M |
| IKNA | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 82.1 M | 163.4 M | 233.1 M | 60.8 M | 121.2 M | 124.4 M |
| XLO | 49 M | 49 M | 49 M | 49 M | 49 M | 49 M | 49 M | 49 M | 49 M | 49 M | 20.8 M | 199.6 M | 121.9 M | 46.3 K | 44 K |
| TARA | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 40 M | 36.4 M | 21.2 M | 19.4 M | 6.2 M | 169.4 M | 36.5 M | 24.9 M | 40.3 M | 50.9 M |
| SRRK | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 56.7 M | 115.3 M | 38.8 M | 162.9 M | 215.3 M | 105.8 M | 104.3 M | 111.3 M |
| GBIO | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 17.2 M | 64.9 M | 380.8 M | 98.9 M | 72.2 M | 118 M |
| KRON | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 32.6 M | 250 M | 200.3 M | 78 M | 66.4 M | 116.9 M |
| ERAS | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 65.7 M | 360.9 M | 284.6 M | 93.5 M | 183.5 M |
| CCCC | 38.9 M | 38.9 M | 38.9 M | 38.9 M | 38.9 M | 38.9 M | 38.9 M | 38.9 M | 38.9 M | 93.1 M | 184.3 M | 79.4 M | 33 M | 130 M | 102.4 M |
| EWTX | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 104.9 M | 15.6 M | 22 M | 86.1 M | 55.5 M |
| OVID | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 69.9 M | 51.9 M | 87.1 M | 36.5 M | 41.9 M | 72 M | 189.7 M | 46.8 M | 29 M | 27.5 M |
| CNTB | 401.6 M | 401.6 M | 401.6 M | 401.6 M | 401.6 M | 401.6 M | 401.6 M | 401.6 M | 401.6 M | 309 M | 154.7 M | 1.7 B | 80.4 M | 106 M | 100.7 M |
| PEPG | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 9.8 M | 134.4 M | 183.2 M | 82.3 M | 90.9 M |
| TYRA | 108 K | 108 K | 108 K | 108 K | 108 K | 108 K | 108 K | 108 K | 108 K | 108 K | 15.5 M | 302.4 M | 252.2 M | 59 M | 56.1 M |
| CMPX | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 25.6 M | 47.3 M | 144.5 M | 34.9 M | 24.2 M | 44.6 M |
| VIGL | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 92.3 M | 187.5 M | 52 M | 97.9 M |
| PRTC | 10.9 M | 10.9 M | 10.9 M | 7.2 M | 62 M | 134.8 M | 63 M | 72.6 M | 117.1 M | 132.4 M | 403.9 M | 465.7 M | 149.9 M | 191.1 M | 165.9 M |
UroGen Pharma and related stocks such as Eliem Therapeutics, Inhibrx, and Merrimack Pharmaceuticals End Period Cash Flow description
My Equities
My Current Equities and Potential Positions
| UroGen Pharma | URGN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Israel |
| Exchange | NASDAQ Exchange |
USD 12.66
Check out UroGen Pharma Performance and UroGen Pharma Correlation. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
UroGen Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.